Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Linola sept Antivirale Mund- und Rachenspülung** is an alcohol-free antiviral mouth-and-throat rinse marketed by Dr. Wolff as a medical device. It is a locally applied surfactant-containing formulation intended to help inactivate and remove specific enveloped viruses in the oral cavity and throat. Its listed ingredients include sodium lauryl sulfate, sodium methyl cocoyl taurate, sodium myristoyl sarcosinate, PEG-40 hydrogenated castor oil, zinc PCA, hydroxyapatite, lactoferrin, and sodium hyaluronate. The proposed antiviral action is non-specific physicochemical disruption of the viral lipid envelope rather than binding to a defined human receptor. A completed randomized placebo-controlled registered study evaluated gargling with the product in people with COVID-19, and the product has also been studied for rhinovirus-associated acute sore throat symptoms. ([linola.com](https://www.linola.com/de-de/cremes-shampoos-co/details/product/linola-sept-antivirale-mund-und-rachenspuelung))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Linola sept Antivirale Mund- und Rachenspülung.